

ELIGA

PID: --A

Visit Date: --

4. Has informed consent/assent been obtained as per applicable regulations?

☐

Yes

☐

No (**Ineligible**)

AINCL04

5. Did the participant agree to the storage of study specimens and use of these specimens for future research?

☐

Yes

☐

No (**Ineligible**)

AINCL05

6. Did the participant agree to the use of stored specimens for future human genetic research?

☐

Yes

☐

No

STORCONS

7. Is the participant enrolled in the Parent Protocol?

☐

Yes

☐

No (**Ineligible**)

AINCL07

8. Has the participant received >1 week (daily or intermittent doses) of any drugs with anti-TB activity within 30 days prior to provisional enrollment, including:

- Any drug or combination of drugs typically used in a multidrug anti-TB therapy (*isoniazid (INH), rifampicin, pyrazinamide, ethambutol*);
- Any *fluoroquinolone* (e.g., *ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin, nalidixic acid, sparfloxacin, and gatifloxacin*);
- Any other drugs with anti-TB activity (e.g., *clofazamine, aminoglycosides (amikacin, kanamycin), or capreomycin*).

☐

Yes (**Ineligible**)

☐

No

AEXCL01

9. Does the participant/participant's guardian have plans to move from his/her current residence, which would interfere with the participant's ability to complete all study visits (through the 6-Month Post-Treatment visit)?

☐

Yes (**Ineligible**)

☐

No

AEXCL02

10. Does the participant have an active psychiatric condition, or alcohol or drug dependence that, in the opinion of the site investigator or designee, might interfere with the ability to give true informed consent and to adhere to the study requirements?

☐

Yes (**Ineligible**)

☐

No

AEXCL03

PID: --**A**

Visit Date: --

11. Is the participant currently imprisoned?

☐ Yes (*Ineligible*) ☐ No **AEXCL04**

12. Was the participant previously enrolled in Cohort B?

☐ Yes ☐ No (*End of form*) **PRIORENRB**

12a. If yes, Participant ID: **PRIORBID** --**B**